4//SEC Filing
Derynck Mika K 4
Accession 0001209191-23-013500
CIK 0001672619other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 9:43 PM ET
Size
6.8 KB
Accession
0001209191-23-013500
Insider Transaction Report
Form 4
Derynck Mika K
Director
Transactions
- Award
Employee Stock Option (right to buy)
2023-02-23+87,373→ 87,373 totalExercise: $2.48Exp: 2031-08-02→ Common Stock (87,373 underlying)
Footnotes (3)
- [F1]The shares underlying the option are subject to an early exercise provision and vest in 48 equal monthly installments beginning on September 2, 2021.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3))
- [F3](continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001865125
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 9:43 PM ET
- Size
- 6.8 KB